



TYRATECH ®
PUTTING NATURE TO WORK

February 2016

Bruno Jactel, CEO
Erica Boisvert, CFO

OVERVIEW




TyraTech is a life science technology company focused on pesticide-free products to control insects and parasites

HIGHLIGHTS


- Unique, safe, effective plant-based technology - 28 granted patents (36 pending)
- Large addressable markets (> \$ 12 billion): consumer, animal health, agriculture
- Several products already launched
- Large distribution of Vamousse head lice: 20,000 stores (USA); 7,000 (UK)
- Global growth strategy: rich pipeline of innovation; geographical expansion

SAFE AND PATENTED FORMULATIONS*

SYNERGISTIC ACTION




SAFE INGREDIENTS



*28 granted patents and 36 pending

VAMOUSSE LICE TREATMENT IN ACTION



TYRATECH BRANDS AND PRODUCTS

Consumer Health

Animal Health

Head Lice

Repellent

Horses

Livestock

VAMOUSSE

GUARDIAN

OUTSMART*


PURESCIENCE



* A SmartPak Brand

VAMOUSSE: EXTENSIVE DISTRIBUTION NETWORK

20,000 stores in the US in 2015



7,000 stores in the UK in 2015



MONETISATION OF OUR TECHNOLOGY

- Commercial success of Vamousse unlocked the value of TyraTech's technology
- TyraTech's strategy is now to extend its technology into other markets
- The next target is to address the unmet needs of the animal health market

Production animals

- Insects transmit diseases and reduce productivity
- Resistance to pesticides
- Pesticides not safe for food chain




Companion animals

- Major concern with fleas and ticks
- Customer demand non-pesticide solution
- Safety for children and pets



PURESCIENCE: LIVESTOCK PREMISES


- The  **PureScience**[™] Solution
 - Complete control of insect population, with up to 90% kill of adults and immatures
 - Effective on pesticide-resistant strains
 - No need to remove animals from premises leading to savings in labour costs
 - Safe for food chain and employees applying these products
- Distribution secured in the USA with the #1 distributor
 - 9 billion chickens in factory farms (USA) and 50 billion worldwide
 - Launched February 2016




FUTURE GROWTH POTENTIAL

The commercial success of Vamousse can be reproduced in significantly larger markets

Current markets*



Future markets*



* At retail level, management estimates and market data

GROWTH PATHWAY

Geographical expansion

- 80% chickens outside USA
- 70% head lice outside USA


Pipeline products

- Patented discovery platform
- 10+ products in pipeline

Market penetration

- Expand distribution
- Increase market share

FINANCIAL HIGHLIGHTS



TyraTech:

- Provides a needed alternative to traditional synthetic pesticides
- With a unique, plant-based, patented technology
- Several successful products already launched in the market
- Vamousse success can be reproduced in bigger markets (animal health)
- Rapid growth strategy: geographical expansion and new products
- Well-funded and has a focused roadmap to achieve profitability

THANK YOU!

See more at www.tyratech.com



Follow us on:

www.facebook.com/tyratech



www.twitter.com/tyratechnews

DISCLAIMER

This presentation has been prepared by TyraTech, Inc. (the “Company”).

The information in this presentation is being given to you solely for your preliminary information on a confidential basis and neither it nor its contents may be reproduced, redistributed or passed on or disclosed, in whole or in part, to any other person. In particular, neither this presentation nor any copy thereof may be taken, transmitted, distributed or sent, directly or indirectly, in or into Australia, the Republic of South Africa, the Republic of Ireland, Japan or Canada or to any resident thereof or in or into the United States or to any US Person (as defined in Regulation S promulgated under the United States Securities Act of 1933 (as amended) (the “Securities Act”). The distribution of this presentation in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of any such other jurisdiction.

Within the United Kingdom this document is directed at and may only be communicated to persons who are both (a) “qualified investors” within the meaning of Article 2(1)(e) of the Prospectus Directive (“Qualified Investors”) or other persons to whom it may lawfully be distributed without giving rise to the requirement for a prospectus under the Prospectus Directive; and (b) either (i) persons who have professional experience in matters relating investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (“FSMA”) (Financial Promotion) Order 2005 (the “Order”); (ii) high net worth entities falling within Article 49 of the Order; or (iii) other persons to whom it may lawfully be communicated, (all such persons together known as “Relevant Persons”).

The content of this document has not been approved for distribution in the United Kingdom by an authorised person. Such approval is required by section 21 of FSMA unless an appropriate exemption applies. Reliance on this document for the purpose of engaging in any investment activity may expose a significant risk of losing all the property invested or of incurring additional liability. If you are in any doubt about the investment to which this document relates you should consult an independent financial adviser or other authorised person under the FCA who specialises in advising on the acquisition or disposal of shares and other securities.

Any investment or investment activity to which this document relates is available in the United Kingdom only to Relevant Persons. Any person who is not a Relevant Person should not act or rely on this presentation or any of its contents and any investment or investment activity to which it relates will only be available to Relevant Persons. Any person who is unsure of their position should seek independent advice.

This document does not constitute a prospectus, and does not constitute, or form part of, any offer to sell or issue, or any solicitation of subscriptions for the Company’s securities, nor should it be relied on in connection with any such sale, issue or subscription.

No Shares have been offered or sold, or will be offered or sold, to the public in any member state of the European Economic Area to anyone other than qualified investors as defined in the Prospectus Directive.

This document may be distributed in Switzerland to qualified Swiss investors only without the use of advertisements.

The information contained in this presentation is subject to updating, completion, verification and amendment and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. None of the Company, its shareholders or any of their respective affiliates, advisers (including SPARK Advisory Partners Limited) or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. The forward-looking information contained herein has been prepared on the basis of a number of assumptions which may prove to be incorrect, and accordingly, actual results may vary. In any event, the value of investments can go up as well as down and past performance is not a guide to future returns.

The securities have not been and will not be registered under the Securities Act or under the securities laws of any state of the United States or under the applicable securities laws of Australia, the Republic of South Africa, the Republic of Ireland, Japan or Canada. Accordingly, subject to certain exceptions, such securities may not, directly or indirectly, be offered, sold, transferred, taken up or delivered in or into the United States of America, Australia, the Republic of South Africa, the Republic of Ireland, Japan or Canada or to or for the account or benefit of any national, resident or citizen of such countries or to any US Person as defined in Regulation S under the Securities Act. No action has been taken or will be taken by the Company or its shareholders or SPARK Advisory Partners Limited that would permit a public offer of shares in the Company or possession or distribution of this presentation where action for that purpose is required.

The Shares have not been recommended by any United States federal or state securities commission or regulatory authority. The foregoing authorities have not confirmed the accuracy of or determined the adequacy of this document. Any representation to the contrary is a criminal offence in the United States. This document has been prepared pursuant to rules and requirements other than those promulgated under the United States federal securities laws and may not contain disclosures customary, expected or required in securities registration transactions prepared pursuant to the US rules and requirements.